Revolution Medicines, Inc. Revolution Medicines, Inc.

Revolution Medicines, Inc.

RVMD

Rangering i aksjer #580
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Aksjekurs
$196.16
Sist synkronisert: 2026-10-20
Markedsverdi
$42.04B
Endring (1 dag)
7.69%
Endring (1 år)
266.72%
Land
US
Handel Revolution Medicines, Inc. (RVMD)

Kategori

Healthcare
Antall utestående aksjer for Revolution Medicines, Inc. (RVMD)
Antall utestående aksjer per June 2026: 210.89M
Ifølge Revolution Medicines, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 210.89M. Ved slutten av December 2023 hadde selskapet 113.15M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Revolution Medicines, Inc. (RVMD) fra 2017 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
2026 (TTM) 210.89M 25.73%
2024 167.74M 48.24%
2023 113.15M 40.34%
2022 80.63M 10.74%
2021 72.81M 9.32%
2020 66.60M 82.60%
2019 36.47M 0.00%
2018 36.47M 0.00%
2017 36.47M 0.00%
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 20.39%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 87.77%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 127.09%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -70.51%
NL